Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of acinetobacter bacteremia

327 728

Cited 34 times in

Authors: Jun Yong Choi ; Chang Oh Kim ; Yoon Seon Park ; Hee Jung Yoon ; So Youn Shin ; Young Keun Kim ; Myung Soo Kim ; Yeon-a Kim ; Young Goo Song ; Dongeun Yong ; Kyungwon Lee ; June Myung Kim

MeSH: Acinetobacter/drug effects ; Acinetobacter/isolation & purification ; Acinetobacter Infections/drug therapy* ; Acinetobacter Infections/mortality ; Adolescent ; Adult ; Aged ; Anti-Bacterial Agents/therapeutic use* ; Bacteremia/drug therapy* ; Cefoperazone/therapeutic use* ; Cilastatin/therapeutic use ; Drug Resistance, Bacterial ; Drug Therapy, Combination ; Female ; Humans ; Imipenem/therapeutic use ; Male ; Middle Aged ; Protease Inhibitors/therapeutic use ; Sulbactam/therapeutic use*

Keywords: Acinetobacter ; bacteremia ; cefoperazone/sulbactam ; imipenem/cilastatin

Abstract: Multiple antibiotic reisistance threatens successful treatment of Acinetobacter baumannii infections worldwide. Increasing interest in the well-known activity of sulbactam against the genus Acinetobacter has been aroused. The purpose of this study was to compare the outcomes for patients with Acinetobacter bacteremia treated with cefoperazone/sulbactam versus imipenem/cilastatin. Forty-seven patients with Acinetobacter baumannii bacteremia were analyzed through a retrospective review of their medical records for antibiotic therapy and clinical outcome. Thirty-five patients were treated with cefoperazone/sulbactam, and twelve patients with imipenem/cilastatin. The percentage of favorable response after 72 hours was not statistically different between cefoperazone/ sulbactam group and imipenem/ cilastatin group. The mortality rate was not statistically different, too. Cefoperazone/sulbactam was found to be as useful as imipenem/cilastatin for treating patients with Acinetobacter bacteremia.